- Home
- PRFX vs BDRX Comparison
PRFX vs BDRX Comparison
Compare PRFX & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- BDRX
- Stock Information
- Founded
- PRFX 2007
- BDRX 2000
- Country
- PRFX Israel
- BDRX United Kingdom
- Employees
- PRFX N/A
- BDRX N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- BDRX Health Care
- Exchange
- PRFX Nasdaq
- BDRX Nasdaq
- Market Cap
- PRFX 3.8M
- BDRX 3.5M
- IPO Year
- PRFX 2020
- BDRX N/A
- Fundamental
- Price
- PRFX $1.88
- BDRX $1.40
- Analyst Decision
- PRFX Hold
- BDRX
- Analyst Count
- PRFX 1
- BDRX 0
- Target Price
- PRFX N/A
- BDRX N/A
- AVG Volume (30 Days)
- PRFX 3.8M
- BDRX 316.2K
- Earning Date
- PRFX 05-14-2025
- BDRX 05-16-2025
- Dividend Yield
- PRFX N/A
- BDRX N/A
- EPS Growth
- PRFX N/A
- BDRX N/A
- EPS
- PRFX N/A
- BDRX N/A
- Revenue
- PRFX N/A
- BDRX N/A
- Revenue This Year
- PRFX N/A
- BDRX N/A
- Revenue Next Year
- PRFX N/A
- BDRX N/A
- P/E Ratio
- PRFX N/A
- BDRX N/A
- Revenue Growth
- PRFX N/A
- BDRX N/A
- 52 Week Low
- PRFX $0.43
- BDRX $1.14
- 52 Week High
- PRFX $16.63
- BDRX $74.00
- Technical
- Relative Strength Index (RSI)
- PRFX 34.67
- BDRX 42.18
- Support Level
- PRFX $2.22
- BDRX $1.28
- Resistance Level
- PRFX $2.41
- BDRX $1.42
- Average True Range (ATR)
- PRFX 0.14
- BDRX 0.09
- MACD
- PRFX -0.02
- BDRX 0.03
- Stochastic Oscillator
- PRFX 6.80
- BDRX 37.84
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.